NCT06672575

A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 45 (estimated)
• Sponsor: M.D. Anderson Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of Phase 1 of this clinical research study is to find the highest tolerable dose and the recommended Phase 2 dose of ivonescimab that can be given to patients who have recurrent glioblastoma. The goal of Phase 2 of this clinical research study is to learn if the recommended Phase 2 dose of ivonescimab found in Phase 1 can help to control the disease.

Detailed description

Primary Objectives: * To determine the safety and tolerability of ivonescimab in adult patients with recurrent glioblastoma * To determine the median progression free survival and progression free survival rate at 6 months of ivonescimab in adult patients with recurrent glioblastoma

Conditions

• Glioblastoma

Interventions

Type	Name	Description
DRUG	Ivonescimab	Participante will recived an infusion by vein

Timeline

• Start date: 2025-01-30
• Primary completion: 2028-01-31
• Completion: 2030-01-31
• First posted: 2024-11-04
• Last updated: 2026-02-27

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study